Nevertheless, strategic inhibition of CD95 signaling to simultaneously block CD95-mediated cancer cell growth and the apoptotic death of cells in the tumor microenvironment with antitumor potential, including CD95-expressing immune effector cells, may represent a suitable alternative therapeutic strategy targeting the CD95-CD95L system. This evidence concerns the gene FASLG and neoplasm.